LAUSR

Aim: There are no guidelines for use of diabetic medications in pancreatic diabetes. Hence we attempted to the benefits of antidiabetic agents in pancreatic diabetes. Materials and methods: a total of 670 chronic pancreatitis patients are selected. Out of that about 126 patients with pancreatic diabetic are selected for the study. The data collected from 2010. Results: In this study mean age was found to be 53.86±12.53. The male patients (73.8%) were more predominant in this study than female patients (26.2%). The complications of chronic pancreatitis among 126 patients, 126 (100) patient had diabetes mellitus (DM), 100 (79) patients had pain. Among 126 patients 52 (41.3%) patients had taken insulin only, 21 (16.7%) patients had taken insulin+ oral combination, 16 (12.7%) patients had taken Biguanides, 13 (10.3%) of patients had taken oral combinations, 13 (10.3%) patients had taken alpha glucosidase inhibitors, 11 (8.7%) patients who are taken sulfonyl ureas. Most of the patients took insulin monotherapy. Conclusion: Insulin was most preferred agent. Metformin was the most commonly preferred oral antidiabetic agent.